ClinicalTrials.gg
RecruitingNCT07213544Updated Nov 20, 2026

Remimazolam vs Propofol in Laser Burn Cases

A Phase 4 interventional study of Remimazolam besylate and Propofol in Burn Scar, Hypertrophic Scarring and Procedural Sedation, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Medical University of South Carolina · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 20, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Cicatrix, Hypertrophic with a site in United States — 7 open to participants now, 8 under way, 2 of them phase 3. Cicatrix, Hypertrophic · United States.

Planned enrollment
Largest of 35
136 · median 22
Started
2025
with 1 other
Phase 4
3 of 38
1 open now
Registered
37th of 38
by date

Among the 38 studies in Cicatrix, Hypertrophic with a site in United States, this one has the largest planned enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 4, and was the 37th registered.

Cicatrix, Hypertrophic

129 studies on the registry are indexed under Cicatrix, Hypertrophic; 31 are open to participants now.

Browse Cicatrix, Hypertrophic studies →

Open to participants now

7 of the 38 studies in Cicatrix, Hypertrophic with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Cicatrix, Hypertrophic studies recruiting now, 8 (42%) set no upper age limit and 10 (53%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Cicatrix, Hypertrophic with a site in United States, or all of them as a file.
02

Study summary

This randomized, single-blind, crossover study compares remimazolam and propofol for monitored anesthetic care during fractional ablative CO₂ laser therapy for burn scars. The primary aim is to assess incidence of respiratory depression, defined as a need for advanced airway maneuvers (jaw thrust/chin lift, insertion of oral or nasal airway, or bag mask ventilation), and hypopnea (respiratory rate \< 8).

Read the detailed description

Patients will be randomized to receive either remimazolam or propofol during their first laser session, and the alternate drug during their second session 4-6 weeks later. Outcomes include respiratory depression, sedation onset and recovery times, hemodynamic changes, and patient satisfaction.

03

Conditions studied

  • Burn Scar
  • Hypertrophic Scarring
  • Procedural Sedation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Undergoing both outpatient Session #1 and Session #2 of fractional ablative CO2 laser therapy

Exclusion criteria

Exclusion Criteria:

  • History of previous fractional ablative laser therapy for burn scar
  • Procedure expected to last longer than 30 minutes
  • Allergy such as dextran 40 or to either of the study drugs
  • Pregnant and/or breastfeeding
  • Subjects who are unable to or choose not to give
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
136 participants (estimated)

Study arms

  • Active comparator
    Remimazolam followed by Propofol

    Patients will be randomized to receive Remimazolam 0.075 mg/kg (maximum of 5 mg) for sedation during their first laser therapy session, then 4-6 weeks later at their next laser therapy session they will receive propofol 0.8 mg/kg IV bolus for sedation.

    Drug: Remimazolam besylate · Drug: Propofol

  • Active comparator
    Propofol followed by Remimazolam

    Patients will be randomized to receive Propofol 0.8 mg/kg IV bolus for sedation during their first laser therapy session, then 4-6 weeks later at their next laser therapy session they will receive Remimazolam 0.075 mg/kg (maximum of 5 mg) for sedation.

    Drug: Remimazolam besylate · Drug: Propofol

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of respiratory depression

    The incidence of respiratory depression will include need for advanced airway maneuvers, or hypopnea events. Advanced airway maneuvers during the laser therapy procedure may include jaw thrust, chin lift, insertion of oral or nasal airway, or bag mask ventilation. A hypopnea event is defined as a respiratory rate \<8.

    Time frame: up to 24 hours after procedure ends

Secondary outcomes

  1. Time from initiation of sedation to peak sedation

    Time from initiation of sedation to peak sedation will be measured in minutes and calculated from the start time of induction to peak sedation when patient reaches a Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score of less than 3. The MOAA/S scale ranges from 0 to 5, with higher scores indicating greater alertness and lower scores indicating deeper sedation: 5: Responds readily to name spoken in a normal tone. 4: Lethargic response to name spoken in a normal tone. 3: Responds only after name is called loudly or repeatedly. 2: Responds only after mild prodding or shaking. 1: Responds only after a painful trapezius squeeze. 0: Does not respond to a painful trapezius squeeze.

    Time frame: up to 24 hours after procedure ends

  2. Time of cessation of sedation to full recovery

    Time of cessation of sedation to full recovery will be evaluated in minutes by marking when the last dose of anesthetic medication is given (cessation of sedation), to when the patient has reached full recovery from anesthesia. Full recovery from anesthesia is defined as when the patient reaches a Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score ≥ 4. The MOAA/S scale ranges from 0 to 5, with higher scores indicating greater alertness and lower scores indicating deeper sedation: 5: Responds readily to name spoken in a normal tone. 4: Lethargic response to name spoken in a normal tone. 3: Responds only after name is called loudly or repeatedly. 2: Responds only after mild prodding or shaking. 1: Responds only after a painful trapezius squeeze. 0: Does not respond to a painful trapezius squeeze.

    Time frame: up to 24 hours after procedure ends

  3. Cessation of sedation to full recovery

    Cessation of sedation to full recovery will also be evaluated as length of PACU stay. This will be measured from the time the patient left the procedure room, to the time they are ready for discharge (marked as procedural care complete).

    Time frame: up to 24 hours after the procedure ends

  4. Satisfaction with Anesthesia

    Satisfaction with Anesthesia will be measured using the Iowa Satisfaction with Anesthesia Scale (ISAS) approximately 15 minutes to two hours after arrival to to the recovery unit. This measures their satisfaction with Monitored Anesthesia Care (MAC). ISAS is an 11-item questionnaire designed to measure the satisfaction with monitored anesthesia care. The ISAS score is the mean of responses to all 11 questions. The score ranges from a minimum of -3 to a maximum of +3 when averaged together. The responses are: -3 = disagree very much, -2 = disagree moderately, -1 = disagree slightly, 1 = agree slightly, 2 = agree moderately, and 3 = agree very much. A score of +3 would imply a completely satisfied patient.

    Time frame: up to 24 hours after the procedure ends

  5. Felling pain on injection of sedation medication

    Subjects will be asked if they felt pain upon the injection of the sedation medications, and will answer "yes" or "no". This will be asked at least 15 minutes after arriving to the recovery area after the procedure. "No" indicates they did not feel pain upon injection which means a better outcome.

    Time frame: up to 24 hours after the procedure ends

Other outcomes

  1. Incidence of hypotension

    Incidence of hypotension during the procedure will measured by the use of vasopressors such as Norepinephrine or equivalent, as well as the lowest blood pressure reading during the procedure.

    Time frame: up to 24 hours after the procedure ends

  2. Incidence of low EtCO2

    Incidence of low EtCO2 will be measured by recording the lowest intraoperative EtCO2 reading during the procedure.

    Time frame: up to 24 hours after the procedure ends

  3. Incidence of hypoxemia

    Baseline SpO2 and lowest SpO2 will be recorded to evaluate incidence of hypoxemia during the procedure.

    Time frame: up to 24 hours after the procedure ends

07

Study locations

1 of 1 sites recruiting
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
    Recruiting
    • Rishi Patel, M.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2025 (actual). Primary completion is estimated for Jan 2028, 25 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Jan 2027 → Jan 2028 and completion Jan 2027 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
Oct 9, 2025
StartActual
Nov 12, 2025
Primary completionEst.
Jan 1, 2028was Jan 2027
CompletionEst.
Jan 1, 2028was Jan 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 1, 2027→Jan 1, 2028
Nov 20, 2026
Study completion
Jan 1, 2027→Jan 1, 2028
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Primary completion Jan 1, 2027→Jan 1, 2028
    Study completion Jan 1, 2027→Jan 1, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07213544
Responsible party
Rishi Patel (Assistant Professor-Faculty, Medical University of South Carolina) — Principal investigator
First posted
Oct 9, 2025
Start date
Nov 12, 2025
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Haley Nitchie
Contact
nitchie@musc.edu
(843) 792-1869
Rishi Patel, MD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Remimazolam besilate · Propofol

Start the discussion